The results are based on an analysis of three open phase I trials and were presented at the Ninth World Conference on Lung Cancer, in Tokyo, Japan, by Dr. Mark Kris, with Memorial Sloan-Kettering Cancer Center in New York, New York. In one of the trials, ZD1839 was administered using an intermittent schedule. In the other two subsequent, larger clinical trials, the compound was given using a continuous schedule. Diarrrhea and acneiform rash were the most common adverse events but were generally mild and reversible when treatment was stopped. Three patients had a partial response and two patients had regression of non-measurable, evaluable disease.
Preliminary analysis suggests an improvement in disease-related symptoms in responding patients.
Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer. All rights reserved.